Italia markets closed

SWTX Jan 2025 45.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
8,600,00 (0,00%)
Alla chiusura: 11:35AM EDT
Schermo intero
Chiusura precedente8,60
Aperto8,60
Denaro7,80
Domanda10,80
Prezzo d'esercizio45,00
Scadenza2025-01-17
Min-Max giorno8,60 - 8,60
Contratto - Min-MaxN/D
Volume11
Open Interest828
  • GlobeNewswire

    SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

    – Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment – – Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – – Highlighted encouraging Phase 1 and 2 clinical data from emerging pipeline programs at AACR and EHA – STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (